Celltrion Inc

Hikma Pharmaceuticals and Celltrion Inc. have signed exclusive licensing agreements to bring six biosimilar treatments to the Middle East and North Africa region.

Celltrion has become the first pharmaceutical company to launch Omlyclo, an omalizumab biosimilar referencing Xolair, in the European market starting with Norway.

Celltrion's EYDENZELT (aflibercept-boav) becomes the first FDA-approved biosimilar to EYLEA for treating multiple retinal diseases including wet AMD, diabetic macular edema, and diabetic retinopathy.

Celltrion launched two biosimilars in Vietnam in 2024, including Remsima for autoimmune diseases and Herzuma for breast and stomach cancer.

The FDA approved tocilizumab-anoh (Avtozma) IV formulation on August 6, 2025, for treating cytokine release syndrome in patients aged 2 years and older.

Amgen and Accord BioPharma reached a settlement agreement on July 16, 2025, resolving patent litigation over Accord's denosumab biosimilar INTP23, with Accord agreeing to delay U.S. market entry until October 1, 2025.

Celltrion has been named the preferred bidder for a large-scale biologics manufacturing facility in the US, with a final agreement expected in early October.

Onconic Therapeutics has initiated Phase 2 clinical trials for Nesuparib, a dual-target anticancer drug that simultaneously inhibits Tankyrase and PARP for advanced and metastatic pancreatic cancer treatment.

A McMaster University-led international study analyzed 93 randomized controlled trials involving over 11,000 participants to identify the most effective treatments for chronic hives.

The FDA has approved Omlyclo (omalizumab-igec) as the first biosimilar interchangeable with Xolair for treating allergic asthma, chronic rhinosinusitis with nasal polyps, chronic urticaria, and food allergies.